Skip to main content

Table 5 SNPs with differential allele-specific expression in the LA for patients with poAF

From: Allele-specific expression in the human heart and its application to postoperative atrial fibrillation and myocardial ischemia

      poAF No poAF  
SNP Gene Chr Location Reads Samples REF/ALT + REF Samples REF/ALT + REF FDR-adjusted p value
rs2230287 GSN 9 124,065,224 10,279 1 1.00 2 0.50 1 × 10–67
rs41267649 CUTA 6 33,384,473 576 1 1.00 2 0.48 4 × 10–40
rs3733570 QDPR 4 17,503,433 538 3 0.46 1 1.00 4 × 10–28
rs114068468 HLA-DPB1 6 33,054,463 572 2 0.55 1 1.00 6 × 10–26
rs2241198 IGFBP5 2 217,539,068 642 1 1.00 3 0.52 2 × 10–25
rs11550240 COX8A 11 63,743,756 4318 1 0.56 1 1.00 2 × 10–20
rs1800215 COL1A1 17 48,265,495 688 2 0.57 1 0.03 1 × 10–19
rs200375051 C7 5 40,972,534 1081 1 0.51 3 1.00 8 × 10–19
rs3762568 FASTKD2 2 207,631,461 518 1 1.00 6 0.51 5 × 10–18
rs45555133 DACT3 19 47,151,717 288 3 0.49 2 1.00 9 × 10–17
rs117770959 ZMIZ2 7 44,807,772 207 3 0.48 1 1.00 1 × 10–8
rs118077107 NEURL4 17 7,221,197 176 1 1.00 4 0.46 5 × 10–8
rs74450883 FAM219B 15 75,193,432 361 2 0.48 1 1.00 9 × 10–7
rs56173620 LAMA2 6 129,722,453 460 2 0.51 1 1.00 2 × 10–6
rs11538698 MGLL 3 127,540,635 662 1 0.49 4 1.00 4 × 10–5
rs79181968 SERPINA3 14 95,080,814 254 1 1.00 3 0.60 9 × 10–5
rs12117552 LMNA 1 156,104,292 886 1 0.50 1 1.00 0.002
kgp10133162 CLDN18 3 137,750,586 188 3 0.11 5 0.60 0.004
rs138684608 TMED10 14 75,643,107 693 1 0.46 1 1.00 0.005
rs147227072 PCOLCE2 3 142,567,193 685 1 0.53 1 1.00 0.007
rs61741262 TNS1 2 218,669,225 3070 3 0.43 9 0.52 0.01
rs574774 ASAH1 8 17,914,883 3591 1 0.68 2 0.76 0.02
rs4280262 LITAF 16 11,647,492 1801 7 0.45 10 0.57 0.04
  1. The table shows the SNPs with different ASE in the LA in patients who had poAF compared with those who did not. Shown is the gene the SNP is located within, the genomic location, number of reads overlapping the SNP, number of heterozygous LA samples for both patient groups, the REF/ALT + REF ratio, and the FDR-adjusted p value for differential ASE between the two patient groups